Nvidia Shares Hit Again After RBC Lowers Price Target

RBC sees lower selling prices for NVDA gaming chips

Dec 27, 2018 at 3:17 PM
facebook twitter linkedin

U.S. stocks are lower following Wednesday's historic rally. Three names in the news are GPU expert Nvidia Corporation (NASDAQ:NVDA), online services provider Live Ventures Inc (NASDAQ:LIVE), and drugmaker BioXcel Therapeutics Inc (NASDAQ:BTAI). Here's what you need to know about shares of NVDA, LIVE, and BTAI today.

RBC Lowers NVDA Price Target

NVDA stock is trading down 5% at $126.47 after a price-target cut to $200 from $230 at RBC. The brokerage firm apparently sees potential pricing headwinds around Nvidia's GTX 1070 gaming chip for 2019, which it expects to keep the shares range bound. The equity has lost more than half its value in the past three months, touching an annual low of $124.46 yesterday.

Short sellers have certainly taken aim at the chipmaker. In the last two reporting periods, short interest rose by 45%, putting almost 18 million shares in the hands of short sellers -- the most since June 2017.

2018 Financials Smack LIVE Stock

Live Ventures stock is getting hammered after the company revealed its full-year financial results for 2018. After jumping out of the gate, the shares have fallen 9.8% to trade at $7.89, plummeting below recent support from the 20-day moving average. This continues the security's long-term descent, as it was trading around $20 this time last year. In fact, short sellers have been in profit-taking mode on LIVE since March, and now hold just 1.7% of the total float.

FDA Designation Sends BTAI Soaring

BioXcel Therapeutics' acute agitation treatment, BXCL501, was given "fast track" status from the Food and Drug Administration (FDA), sending the stock up 70% at $4.09. The shares -- which began trading publicly at $11 back in March -- hit an all-time low of $2.41 yesterday, and topped out near their 50-day moving average earlier.

We'll see if any analysts downwardly revise their outlooks on BTAI stock, considering this long-term technical weakness. For now, all five brokerage firms in coverage recommend buying the biopharma concern, and the average price target stands as high as $18.20.



Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners